Medical cannabis a valuable option for cancer pain relief
A new study conducted at the RI-MUHC suggests that, as a complementary therapy for cancer patients, medical cannabis could be used safely...
New funding to address chemotherapy resistance in esophageal cancer
RI-MUHC researchers have received $7.5 million from the Canadian Cancer Society and the Canadian Institutes of Health...
Fiera Capital and the MUHC Foundation announce the winners of new awards
Fiera Capital Awards for Diversity, Equity and Inclusion in Health Care Research provide critical funding to young...
Too much pruning: A new study sheds light on how neurodegeneration occurs in the brain
A Montreal research team demonstrates how genetic mutations cause brain cell...
Picture a Scientist: the RI-MUHC marks International Women’s Day with film screening and discussion
A panel of RI-MUHC women scientists and allies discuss the roles of women in science
Panel discussion at the RI-MUHC marks International Day of People Living with Disabilities
Experts and advocates joined the RI-MUHC community to discuss integrating people with disabilities into work...
RI-MUHC trainee wins best presentation award at the 2022 Congrès provincial de la recherche Mère-Enfant
Doctoral student Wajih Jawhar demonstrates that epigenetic...
Liquid biopsy research: a generous boost to help children with cancer
A Montreal research team, headed by the eminent Janusz Rak, PhD, continues to lead the way to the “next frontier” in pediatric cancer screening, diagnosis...
Canada's Top 40 Research Hospitals: three years in the top 3!
Thanks to RI-MUHC researchers, trainees and staff, the MUHC maintains its leadership position in the Canadian research ecosystem
Triple-negative breast cancer: the RI-MUHC enrolls first patients in international Phase 3 clinical trial
The first participants in this large study were recently selected at the Cedars Cancer Centre of the MUHC.